[1] TETTERTON-KELLNER J, JENSEN B C, NGUYEN J. Navigating cancer therapy induced cardiotoxicity: From pathophysiology to treatment innovations[J]. Adv Drug Deliv Rev, 2024, 211: 115361.
[2] 满缓, 张凤, 黄豆豆, 等. 升陷汤及各单味药对阿霉素致心肌细胞损伤的保护作用[J]. 药学实践杂志, 2019, 37(4): 304-308.
[3] HUANG C Y, QIU S, FAN X C, et al. Evaluation of the effect of Shengxian Decoction on doxorubicin-induced chronic heart failure model rats and a multicomponent comparative pharmacokinetic study after oral administration in normal and model rats[J]. Biomed Pharmacother, 2021, 144: 112354.
[4] CHEN S, CHEN J W, DU W T, et al. PDE10A inactivation prevents doxorubicin-induced cardiotoxicity and tumor growth[J]. Circ Res, 2023, 133(2): 138-157.
[5] ZHANG S, LIU X B, BAWA-KHALFE T, et al. Identification of the molecular basis of doxorubicin-induced cardiotoxicity[J]. Nat Med, 2012, 18(11): 1639-1642.
[6] YIN J, GUO J B, ZHANG Q, et al. Doxorubicin-induced mitophagy and mitochondrial damage is associated with dysregulation of the PINK1/parkin pathway[J]. Toxicol In Vitro, 2018, 51: 1-10.
[7] ZHUANG J, MA W Z, LAGO C U, et al. Metabolic regulation of oxygen and redox homeostasis by p53: Lessons from evolutionary biology?[J]. Free Radic Biol Med, 2012, 53(6): 1279-1285.
[8] TAN N N, LUO H W, LI W L, et al. The dual function of autophagy in doxorubicin-induced cardiotoxicity: Mechanism and natural products[J]. Semin Cancer Biol, 2025, 109: 83-90.
[9] CAPPETTA D, ESPOSITO G, PIEGARI E, et al. SIRT1 activation attenuates diastolic dysfunction by reducing cardiac fibrosis in a model of anthracycline cardiomyopathy[J]. Int J Cardiol, 2016, 205: 99-110.
[10] SHI S X, CHEN Y, LUO Z J, et al. Role of oxidative stress and inflammation-related signaling pathways in doxorubicin-induced cardiomyopathy[J]. Cell Commun Signal, 2023, 21(1): 61.
[11] WANG J H, JIANG Y L, ZHU C, et al. Mitochondria-engine with self-regulation to restore degenerated intervertebral disc cells via bioenergetic robust hydrogel design[J]. Bioact Mater, 2024, 40: 1-18.
[12] ABDELGHFFAR E A, OBAID W A, ELGAMAL A M, et al. Pea(Pisum sativum)peel extract attenuates DOX-induced oxidative myocardial injury[J]. Biomed Pharmacother, 2021, 143: 112120.
[13] HAN H, ZHANG G J, ZHANG X, et al. Nrf2-mediated ferroptosis inhibition: a novel approach for managing inflammatory diseases[J]. Inflammopharmacology, 2024, 32(5): 2961-2986.
[14] XIE L H, FEFELOVA N, PAMARTHI S H, et al. Molecular mechanisms of ferroptosis and relevance to cardiovascular disease[J]. Cells, 2022, 11(17): 2726.
[15] ICHIKAWA Y, GHANEFAR M, BAYEVA M, et al. Cardiotoxicity of doxorubicin is mediated through mitochondrial iron accumulation[J]. J Clin Invest, 2014, 124(2): 617-630.
[16] HAN Q C, SHI J L, YU Y D, et al. Calycosin alleviates ferroptosis and attenuates doxorubicin-induced myocardial injury via the Nrf2/SLC7A11/GPX4 signaling pathway[J]. Front Pharmacol, 2024, 15: 1497733.
[17] RIBEIRO A P D, PEREIRA A G, TODO M C, et al. Pera orange (Citrus sinensis) and Moro orange (Citrus sinensis (L.)Osbeck) juices attenuate left ventricular dysfunction and oxidative stress and improve myocardial energy metabolism in acute doxorubicin-induced cardiotoxicity in rats[J]. Nutrition, 2021, 91-92: 111350.
[18] KHALIL H, KANISICAK O, PRASAD V, et al. Fibroblast-specific TGF-β-Smad2/3 signaling underlies cardiac fibrosis[J]. J Clin Invest, 2017, 127(10): 3770-3783.
[19] OCTAVIA Y, TOCCHETTI C G, GABRIELSON K L, et al. Doxorubicin-induced cardiomyopathy: from molecular mechanisms to therapeutic strategies[J]. J Mol Cell Cardiol, 2012, 52(6): 1213-1225.
[20] HANNA A D, LAM A, THAM S, et al. Adverse effects of doxorubicin and its metabolic product on cardiac RyR2 and SERCA2A[J]. Mol Pharmacol, 2014, 86(4): 438-449.
[21] TSCHESCHNER H, MEINHARDT E, SCHLEGEL P, et al. CaMKII activation participates in doxorubicin cardiotoxicity and is attenuated by moderate GRP78 overexpression[J]. PLoS One, 2019, 14(4): e0215992.
[22] SHI H, YANG S A, BAI L Y, et al. Mechanism of myocardial damage induced by doxorubicin via calumenin-regulated mitochondrial dynamics and the calcium-Cx43 pathway[J]. World J Cardiol, 2025, 17(5): 104839.
[23] LIU X F, TIAN R M, TAO H L, et al. The cardioprotective potentials and the involved mechanisms of phenolic acids in drug-induced cardiotoxicity[J]. Eur J Pharmacol, 2022, 936: 175362.
[24] FITZGERALD K A, KAGAN J C. Toll-like receptors and the control of immunity[J]. Cell, 2020, 180(6): 1044-1066.
[25] WANG Q, WANG B L, TIAN X X, et al. Cardamonin protects against doxorubicin-induced cardiotoxicity in mice by restraining oxidative stress and inflammation associated with Nrf2 signaling[J]. Biomed Pharmacother, 2020, 122: 109547.
[26] CHEN X H, TIAN C, ZHANG Z Q, et al. Astragaloside IV inhibits NLRP3 inflammasome-mediated pyroptosis via activation of nrf-2/HO-1 signaling pathway and protects against doxorubicin-induced cardiac dysfunction[J]. Front Biosci, 2023, 28(3): 45.
[27] SZTOLSZTENER K, HODUN K, CHABOWSKI A. α-lipoic acid ameliorates inflammation state and oxidative stress by reducing the content of bioactive lipid derivatives in the left ventricle of rats fed a high-fat diet[J]. Biochim Biophys Acta BBA Mol Basis Dis, 2022, 1868(9): 166440.
[28] 周浩明, 乐世俊, 刘文娟, 等. 经典名方升陷汤的研究进展及质量标志物的预测分析[J]. 中国现代中药, 2024, 26(3): 550-565.
[29] JIAO G Y, WANG Y J, SONG Y, et al. Combination of ultra-performance liquid chromatography-quadrupole time-of-flight mass spectrometry and network pharmacology to reveal the key effective compounds and mechanism of Shengxian decoction for ameliorating doxorubicin cardiotoxicity[J]. J Sep Sci, 2024, 47(9-10): e2300867.
[30] 孙美, 张凤, 范香成, 等. 基于多指标成分测定的正交试验法优选升陷汤提取工艺[J]. 中华中医药杂志, 2022, 37(12): 7423-7427.
[31] HU Y C, YU J Z, HE W X, et al. Astragaloside IV intervenes multi-regulatory cell death forms against doxorubicin-induced cardiotoxicity by regulating AMPKα2 pathway[J]. Int Immunopharmacol, 2024, 142: 113078.
[32] 王巧巧, 李响响, 田萍, 等. 黄芪甲苷对心力衰竭大鼠心肌纤维化及TGF-β/Smad2信号通路的影响[J]. 实用中医内科杂志, 2025, 39(7): 141-143,后插8.
[33] WAN S T, QI J Y, XIA Y, et al. Cardiac Slc25a49-mediated energy reprogramming governs doxorubicin-induced cardiomyopathy through the G6P–AP-1–sln axis[J]. Adv Sci, 2025, 12(26): 2502163.
[34] AGUSTINI F D, AROZAL W, LOUISA M, et al. Cardioprotection mechanism of mangiferin on doxorubicin-induced rats: Focus on intracellular calcium regulation[J]. Pharm Biol, 2016, 54(7): 1289-1297.
[35] YU X Y, HAN Z D, GUO L L, et al. The novel combination of astragaloside IV and formononetin protects from doxorubicin-induced cardiomyopathy by enhancing fatty acid metabolism[J]. Chin J Nat Med, 2025, 23(10): 1171-1182.
[36] LIN J M, FANG L J, LI H, et al. Astragaloside IV alleviates doxorubicin induced cardiomyopathy by inhibiting NADPH oxidase derived oxidative stress[J]. Eur J Pharmacol, 2019, 859: 172490.
[37] 沈丽娟, 陆曙, 蔺莉霞, 等. 黄芪甲苷对阿霉素诱导大鼠心肌细胞凋亡的抑制作用[J]. 江苏医药, 2017, 43(15): 1057-1061.
[38] JIA Y Y, ZUO D Y, LI Z Q, et al. Astragaloside IV inhibits doxorubicin-induced cardiomyocyte apoptosis mediated by mitochondrial apoptotic pathway via activating the PI3K/Akt pathway[J]. Chem Pharm Bull, 2014, 62(1): 45-53.
[39] 王雪丽, 陈亚男, 黄厚芹, 等. 黄芪甲苷通过抑制MerTK缓解阿霉素引起的心脏毒性[J]. 蚌埠医学院学报, 2021(6): 717-721.
[40] SHANG W, LI X H, ZENG L H, et al. Mechanistic insights into flavonoid subclasses as cardioprotective agents against doxorubicin-induced cardiotoxicity: a comprehensive review[J]. Drug Des Dev Ther, 2025, 19: 5553-5596.
[41] 杨秀娟, 田一虹, 杨志军, 等. 基于网络药理学和分子对接的红芪活性成分抗阿霉素心肌毒性的分子机制研究[J]. 中国药物化学杂志, 2021, 31(3): 209-219.
[42] LELE K A, PATIL P P, KAKADE S V, et al. Targeting cardiotoxicity: the potential of Annona squamosa L. in doxorubicin therapy[J]. Silico Pharmacol, 2025, 13(1): 47.
[43] YARMOHAMMADI F, REZAEE R, KARIMI G. Natural compounds against doxorubicin-induced cardiotoxicity: a review on the involvement of Nrf2/ARE signaling pathway[J]. Phytother Res, 2021, 35(3): 1163-1175.
[44] SAHU R, DUA T K, DAS S, et al. Wheat phenolics suppress doxorubicin-induced cardiotoxicity via inhibition of oxidative stress, MAP kinase activation, NF-κB pathway, PI3K/Akt/mTOR impairment, and cardiac apoptosis[J]. Food Chem Toxicol, 2019, 125: 503-519.
[45] ISMAIL M B, RAJENDRAN P, ABUZAHRA H M, et al. Mangiferin inhibits apoptosis in doxorubicin-induced vascular endothelial cells via the Nrf2 signaling pathway[J]. Int J Mol Sci, 2021, 22(8): 4259.
[46] ZHANG Y J, WU S S, CHEN X M, et al. Saikosaponin D alleviates DOX-induced cardiac injury in vivo and in vitro[J]. J Cardiovasc Pharmacol, 2022, 79(4): 558-567.
[47] ZHANG H L, WENG J F, SUN S M, et al. Ononin alleviates endoplasmic reticulum stress in doxorubicin-induced cardiotoxicity by activating SIRT3[J]. Toxicol Appl Pharmacol, 2022, 452: 116179.
[48] GONG G W, GANESAN K, XIONG Q P, et al. Anti-invasive and anti-migratory effects of ononin on human osteosarcoma cells by limiting the MMP2/9 and EGFR-Erk1/2 pathway[J]. Cancers, 2023, 15(3): 758.
[49] 李文标, 徐缘博, 沈隽吉, 等. 基于网络药理学和分子对接探讨炙黄芪拮抗阿霉素心肌损伤的机制研究[J]. 中药药理与临床, 2022, 38(1): 110-118.
[50] ZHANG L, FAN C D, JIAO H C, et al. Calycosin alleviates doxorubicin-induced cardiotoxicity and pyroptosis by inhibiting NLRP3 inflammasome activation[J]. Oxid Med Cell Longev, 2022, 2022: 1733834.
[51] 吴枝娟, 余靖, 王瑞幸, 等. 阿魏酸预处理对阿霉素诱导H9 c2心肌细胞损伤的保护作用[J]. 中国药理学通报, 2014, 30(8): 1059-1065.
[52] 唐炜, 叶鹏林, 刘坤, 等. 咖啡酸对阿霉素心肌细胞损伤的保护作用及机制研究[J]. 安徽医科大学学报, 2022, 57(3): 402-407.